心肌缺血,吃什么药效果好?听听药师怎么说

2023-04-18 心内之友 心内之友 发表于上海

心肌缺血的治疗主要以改善缺血、减轻症状为主,对急性期的患者,可以使用作用较快的硝酸酯类药物。

心肌缺血并非疾病,而是由于冠状动脉狭窄、痉挛或栓塞所引起的,心肌供血、供氧不足的一种病理生理状态,会影响心脏的泵血收缩和舒张功能。

冠心病是引起心肌缺血最常见的病因高血压、血脂异常、糖尿病、吸烟、酗酒、熬夜、肥胖等不良生活习惯可促进冠心病的发生和发展,此外,X综合征、血管痉挛性心绞痛、心肌桥、心动过速等也可导致心肌缺血。

心肌缺血的临床表现具有明显的个体差异,部分患者无明显症状,有症状的患者主要表现为心前区不适、疼痛,多在运动过程在发生,运动停止后往往能自行缓解,还有一部分患者出现一些不典型症状,如恶心、呕吐、上腹痛、下颌痛、咳嗽、气短、出虚汗、乏力、呼吸困难等。

心肌缺血的治疗主要以改善缺血、减轻症状为主,对急性期的患者,可以使用作用较快的硝酸酯类药物,如硝酸甘油、硝酸异山梨酯等,舌下含服,吸收、起效迅速,不仅能够扩张冠状动脉,降低阻力,增加冠状动脉循环血流量,还能扩张外周血管,减少静脉回心血量,降低心室容量、心脏内压、血压以及心排出量,减低心脏负荷和心肌需氧,从而缓解心肌缺血。

对心肌缺血稳定期的患者,可以选择的药物包括:

1、硝酸酯类药物:如硝酸异山梨酯、单硝酸异山梨酯等,这类药物主要的作用是扩张血管,从而减少心肌需氧,改善心肌灌注,减轻心肌缺血症状,增加运动耐量,注意每天用药时应给予足够的无药间期,以减少耐药性发生。

2、钙通道阻滞剂:如硝苯地平控释片、氨氯地平等,这类药物能抑制心肌收缩,减少心肌耗氧,扩张冠状动脉,解除冠脉痉挛,改善心肌供血,扩张外周小动脉,降低血压,减轻心脏负荷,还能降低血黏度,抑制血小板聚集,改善心肌微循环。

3、β受体拮抗剂:如美托洛尔片、美托洛尔缓释片、比索洛尔等,这类药物能减慢心率、减弱心肌收缩力、降低血压,从而降低心肌耗氧量,改善心肌缺血,增加运动耐量。

4、其他:曲美他嗪通过抑制脂肪酸氧化和增加葡萄糖代谢,提高氧的利用效率而改善心肌缺血。尼可地尔属于钾离子通道开放剂,与硝酸酯类药物作用机制相似。中医药治疗心肌缺血以活血化瘀、芳香通温、祛痰活络为主,常用药物如复方丹参滴丸、速效救心丸、麝香保心丸等。

对于比较严重的心肌缺血应该使用阿司匹林或氯吡格雷等抗血小板聚集的药物,对于伴有血脂异常的心肌缺血患者,应该使用他汀类调血脂药,对于合并高血压、糖尿病、心力衰竭或左心室收缩功能不全的高危患者,应该使用依那普利、贝那普利等普利类降压药或氯沙坦、缬沙坦、厄贝沙坦等沙坦类降压药

中成药治疗心肌缺血目前以活血化瘀、芳香通温和祛痰通络法最为常用,常用的中成药包括:

1、复方丹参滴丸:

复方丹参滴丸属于活血化瘀类中成药,具有活血化瘀、理气止痛之功效,由丹参、三七和冰片组成,丹参为君药,活血祛瘀、通行血脉,三七为臣药,化瘀通络止痛,二者配伍具有协同互补效应,冰片为佐使药,芳香走窜,促进丹参和三七中的有效成分进入组织和器官。

人体临床研究证实,复方丹参滴丸可显著改善心肌缺血的临床症状和心电图缺血表现,预防心肌缺血进展,可与常规西药联合用于心肌缺血的长期治疗。

2、麝香保心丸:

麝香保心丸属于芳香温通类中成药,具有芳香温通,益气强心之功效,由人工麝香、人参、人工牛黄、肉桂、苏合香、蟾酥和冰片组成,人工麝香为君药,活血化瘀,开通诸窍,人参补益心气,苏合香芳香温通,辟秽开窍,二者共为臣药。

肉桂温通补阳,益气温阳,强心通脉,人工牛黄开窍醒神,蟾酥开窍止痛,三者共为佐药。冰片为使药,开窍清热止痛。

人体临床研究证实,麝香保心丸具有改善心肌缺血,抑制心室重构、调节血脂、改善内皮功能等作用,是治疗心肌缺血可靠的辅助用药。

3、速效救心丸:

速效救心丸同样属于活血化瘀类中成药,具有行气活血,祛瘀止痛之功效,由川芎和冰片组成,川芎活血行气、化瘀止痛,冰片开窍醒神、辛散止痛,二者配伍可充分发挥药物辛香走窜之力,提高药效。

人体临床试验证实,速效救心丸可改善心肌供血和缺血心电图表现,具有明确抗心肌缺血作用,适用于心肌缺血的辅助治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2130433, encodeId=b38a21304338d, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Sat May 06 11:46:47 CST 2023, time=2023-05-06, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127010, encodeId=ce3c212e010dc, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Wed Apr 19 11:59:57 CST 2023, time=2023-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2126939, encodeId=3f96212693976, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Wed Apr 19 06:29:42 CST 2023, time=2023-04-19, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2126864, encodeId=fa972126864d1, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue Apr 18 21:56:50 CST 2023, time=2023-04-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2126861, encodeId=a059212686155, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Tue Apr 18 21:54:13 CST 2023, time=2023-04-18, status=1, ipAttribution=山东省)]
    2023-05-06 manny.L 来自浙江省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2130433, encodeId=b38a21304338d, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Sat May 06 11:46:47 CST 2023, time=2023-05-06, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127010, encodeId=ce3c212e010dc, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Wed Apr 19 11:59:57 CST 2023, time=2023-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2126939, encodeId=3f96212693976, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Wed Apr 19 06:29:42 CST 2023, time=2023-04-19, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2126864, encodeId=fa972126864d1, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue Apr 18 21:56:50 CST 2023, time=2023-04-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2126861, encodeId=a059212686155, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Tue Apr 18 21:54:13 CST 2023, time=2023-04-18, status=1, ipAttribution=山东省)]
    2023-04-19 manny.L 来自浙江省

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2130433, encodeId=b38a21304338d, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Sat May 06 11:46:47 CST 2023, time=2023-05-06, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127010, encodeId=ce3c212e010dc, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Wed Apr 19 11:59:57 CST 2023, time=2023-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2126939, encodeId=3f96212693976, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Wed Apr 19 06:29:42 CST 2023, time=2023-04-19, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2126864, encodeId=fa972126864d1, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue Apr 18 21:56:50 CST 2023, time=2023-04-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2126861, encodeId=a059212686155, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Tue Apr 18 21:54:13 CST 2023, time=2023-04-18, status=1, ipAttribution=山东省)]
    2023-04-19 ms2000000702445417 来自湖南省

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2130433, encodeId=b38a21304338d, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Sat May 06 11:46:47 CST 2023, time=2023-05-06, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127010, encodeId=ce3c212e010dc, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Wed Apr 19 11:59:57 CST 2023, time=2023-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2126939, encodeId=3f96212693976, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Wed Apr 19 06:29:42 CST 2023, time=2023-04-19, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2126864, encodeId=fa972126864d1, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue Apr 18 21:56:50 CST 2023, time=2023-04-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2126861, encodeId=a059212686155, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Tue Apr 18 21:54:13 CST 2023, time=2023-04-18, status=1, ipAttribution=山东省)]
    2023-04-18 医鸣惊人 来自山西省

    认真学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2130433, encodeId=b38a21304338d, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Sat May 06 11:46:47 CST 2023, time=2023-05-06, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127010, encodeId=ce3c212e010dc, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230412/7f4409075a2847aea5d6fdb1ed77e1c1/afb81e82b8894278bf02e15e5c56100f.jpg, createdBy=8bba6454600, createdName=manny.L, createdTime=Wed Apr 19 11:59:57 CST 2023, time=2023-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2126939, encodeId=3f96212693976, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Wed Apr 19 06:29:42 CST 2023, time=2023-04-19, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2126864, encodeId=fa972126864d1, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue Apr 18 21:56:50 CST 2023, time=2023-04-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2126861, encodeId=a059212686155, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Tue Apr 18 21:54:13 CST 2023, time=2023-04-18, status=1, ipAttribution=山东省)]
    2023-04-18 1013100771 来自山东省

    谢谢分享

    0

相关资讯

FFR在冠状动脉左主干病变中的应用

冠脉介入治疗技术日益成熟和广泛开展的今天,如何更加合理地评估冠脉病变

JE:网络药理学分析与实验验证探讨参莲提取物对心肌缺血的作用机制

从网络药理学的角度探讨参莲提取物在心肌缺血中的潜在分子机制,并通过体内外实验进行验证。

Circ Res:哈尔滨医科大学潘振伟/杨宝峰发现心肌缺血/再灌注损伤的调控新机制

ASPP1 (apoptosis stimulating of p53 protein 1)作为p53的辅助因子,促进其在细胞核内的转录活性,在调节细胞凋亡中起重要作用。

无症状慢性冠脉综合征患者,有必要查心肌缺血吗?主要考虑这4点

慢性冠脉综合征包括急性冠脉事件后病情稳定的患者,有冠脉血运重建(冠脉介入治疗或冠脉搭桥手术)史者,以及没有急性心梗或血运重建病史的稳定性冠心病患者。

最新专家共识推荐!此药可显著改善急性冠脉综合征患者症状

急性冠脉综合征是由于冠状动脉狭窄、引起心肌缺血所致的一类缺血性心脏病, 它是ST段抬高性心肌梗死非ST段抬高性心肌梗死和不稳定性心绞痛的总称其共同病理生理表现的总称是动脉粥样斑块破裂或侵蚀。

JACC:空气污染与心肌缺血患者的冠状动脉舒缩障碍相关

暴露于PM2.5和PM10较高的环境下与心肌缺血和NOCAD患者的冠状动脉血管舒缩异常相关

拓展阅读

患者心肌缺血,麻醉医师需要了解这些机制

缺血是一种缺氧状态,同时伴灌注减少所导致的代谢产物滞留。临床上,心肌缺血是血流供需比的降低,导致功能受损。心肌缺血没有普遍接受的金标准。

Basic Res Cardiol 安徽医科大学第二附属医院何淑芳/张野团队揭示脊髓LPA/TRPV1信号调控心肌缺血损伤

该研究了脑脊液LPA通过作用于脊髓中TRPV1受体调控心肌缺血再灌注损伤的新机制。

清晰!从心肌缺血进展到心肌梗死的心电图改变

本期介绍由心肌缺血进展到心肌梗死的心电图改变。

European Radiology:冠状动脉外脂肪组织的放射组学特征在检测功能性心肌缺血中的诊断价值

心外膜脂肪组织(EAT)是位于心脏和内脏心包之间的内脏脂肪组织,是心脏的内脏脂肪库。

European Radiology:非酒精性脂肪性肝病与心肌缺血有何相关性?

现阶段,冠状动脉CT血管造影(CCTA)已成为评估冠状动脉疾病(CAD)的可靠工具,并被证明在描述冠状动脉狭窄时与有创冠状动脉造影(ICA)具有高度一致性。

怎样的胸痛提示心肌缺血?医生教你这样判断!

说起"心肌缺血"很多人都不陌生,也有不少人知道心肌缺血时,会出现胸闷胸痛等症状,然而,不是所有胸闷胸痛都是心肌缺血,我们必须仔细鉴别。

2016 心理应激导致稳定性冠心病患者心肌缺血的诊断与治疗专家共识

中国医师协会全科分会 双心(心脏心理)学组 · 2016-01-30